KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC

Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Future oncology (London, England) England), 2020-04, Vol.16 (10), p.507-516
Hauptverfasser:	Kamat, Ashish M, Shore, Neal, Hahn, Noah, Alanee, Shaheen, Nishiyama, Hiroyuki, Shariat, Shahrokh, Nam, Kijoeng, Kapadia, Ekta, Frenkl, Tara, Steinberg, Gary
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological - therapeutic use Bacillus Calmette-Guérin BCG Vaccine - therapeutic use Bladder cancer Cancer therapies Chemotherapy Clinical Trials, Phase III as Topic Cytotoxicity Humans Immunotherapy Induction therapy Ligands Metastasis Monoclonal antibodies nonmuscle-invasive bladder cancer pembrolizumab programmed death 1 programmed death ligand 1 Randomized Controlled Trials as Topic Targeted cancer therapy Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!